Keybanc Maintains Overweight on ICU Medical, Raises Price Target to $147
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 08 2024
0mins
Source: Benzinga
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICUI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICUI
Wall Street analysts forecast ICUI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICUI is 173.50 USD with a low forecast of 172.00 USD and a high forecast of 175.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 150.030
Low
172.00
Averages
173.50
High
175.00
Current: 150.030
Low
172.00
Averages
173.50
High
175.00
About ICUI
ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ICU Medical to Present Innovative Products at 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: ICU Medical will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 1:30 PM PT, showcasing its innovations in medical products, which is expected to attract significant investor interest.
- One-on-One Meetings: The management team will also engage in one-on-one meetings on the same day, aiming to deepen connections with potential investors and foster future capital collaborations, enhancing the company's market presence.
- Live Webcast: The presentation will be webcast live on the company's website, allowing viewers to access and replay the session, which increases transparency and broadens its influence in the healthcare sector.
- Company Background: ICU Medical focuses on the development and sale of infusion systems and high-value critical care products, committed to providing quality and innovation to clinical customers worldwide, underscoring its leadership position in the medical industry.
Continue Reading
Insiders Purchase Shares of VHT ETF Holdings
Insider Buying in Vanguard Health Care ETF: 17.6% of the weighted holdings in the Vanguard Health Care ETF (VHT) have seen insider buying in the past six months.
ICU Medical Inc Activity: ICU Medical Inc (ICUI), making up 0.05% of VHT, has had two directors and officers purchase shares recently, with the ETF holding $9,411,006 worth of ICUI.
Tandem Diabetes Care Inc Activity: Tandem Diabetes Care Inc (TNDM), the #243 largest holding in VHT, also shows insider buying from two directors and officers, with the ETF holding $3,407,114 worth of TNDM.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect those of Nasdaq, Inc.
Continue Reading